BJDX Bluejay Diagnostics Inc

$BJDX BEPPELS WL 23.09.: - $BJDX, 0.97 $, 4.5 mln float, 1.8 $ cash per share, funded for 16 months, FDA data due! ✅ - $SDST, 0.12 $, 38 mln float, penny near lows, hit 0.4 $ just last week! ✅ - $SWRD, 2.1 $, 9.75 mln float, recent uplister from otc, 100 % room to otc closing price! ✅ - $LABT, 2 $, 1.6 mln float, 751 % ctb, bio near lows, sympathy to $JAGX! ✅ 👀 🔥 👀

$BJDX $GLND $YMT nothing pleases me more than taking a ton of profit today and then buying it back on discount from all these lazy 0 research day traders 🫡🔥🔥🔥 Next up - 2.7 merger offer and free $1.50 warrants

$BJDX | Snapshot 📊🧪• Business: Near-patient diagnostic medical technology developer advancing the proprietary Symphony System for rapid whole-blood biomarker testing in critical care settings.• Financial Health & Pipeline: Completed enrollment in the pivotal SYMON-II clinical trial for its lead Symphony IL-6 sepsis risk test ahead of planned FDA 510(k) submission.• Bias & Conviction: Bottoming Watch | Speculative Conviction (Monitoring for a reclaim of $1.02 volume resistance following extended range contraction near $0.80 support). 🎯 Key Levels: 🐂 Bull Trigger: $1.02 / $1.25 🚀 Targets: $1.45 / $2.00 / $2.52 🛡️ Support: $0.89 / $0.80 ⚠️ Risk: $0.80 / $0.67 #BJDX #biotech #medtech #finance #hovdid

If your looking to spot those big runners early before they squeeze.. Make sure to start Following below. He's actually pretty good 💯🤑 Looking forward for the next banger 🔥 $BJDX & $AISP looking good for more

$BJDX is moving on clinical trial results following a ACCESSWIRE release. Bluejay Diagnostics announces SYMON-II clinical study results showing IL-6 biomarker evaluation in 777 sepsis patients with 18% mortality rate. RTPR pushed this release out to users at 6:30:00 AM ET

$BJDX Now is the time to buy when idiots got wiped out chasing the pump. The real move hasn't been made yet

$BJDX ATM tap turned off for now, warrants not to far down either Resale shares kinda off so need like 10 mil volume day for this to run

$BJDX Armistice...are you the cocksuckers shorting this right now you POS bank?? I know you want to cash in on those warrants you fukin toxic leeches. Didn't you get your fill today with DCOY?! You rat bastards.

$BJDX — Bluejay Diagnostics' Symphony IL-6 product advancement and clinical study milestones contrasted with persistent financial losses and bearish technical indicators. Upside discussed: Successful completion of enrollment in the SYMON-II clinical validation study. Strengthened balance sheet to support product advancement. Risk discussed: Consistent net losses and operating losses reported annually and quarterly. Zero reported revenue and gross profit for fiscal years 2022 and 2023. Recent analyses for Bluejay Diagnostics (BJDX) covered the advancement of its Symphony™ IL-6 product towards regulatory submission, supported by a strengthened balance sheet and the successful completion of the SYMON-II clinical validation study. Concurrently, the analyses noted the company's consistent net losses, lack of revenue, and significant bearish technical indicators including prices below key moving averages and negative MACD readings.

$BJDX good news and 6.2 millions of shares traded and the value is still 0.79. It’s pretty sad.

$BJDX today’s SYMON-II update gives preliminary data on 777 patients, including 140 deaths at 28 days, and the company says the study is intended to support a future FDA 510(k) application.

$BJDX Armistice, you cucks! What are you doing here? You don't wanna cash in on those warrants?